EGFR and neoplasm: In particular, Transtinib, irreversibly and selectively targets both sensitizing and resistant-L858R/T790M mutant EGFR with activity toward the interactive residues (Met790/793 and Cys797) of the nucleotide binding pocket, showing promising therapeutic responses in both tumor cells and mouse models.